On Friday, Protagonist Therapeutics Inc (NASDAQ: PTGX) opened higher 4.23% from the last session, before settling in for the closing price of $40.89. Price fluctuations for PTGX have ranged from $24.22 to $60.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 2607.12% over the last five years. Company’s average yearly earnings per share was noted -130.94% at the time writing. With a float of $57.88 million, this company’s outstanding shares have now reached $61.04 million.
The firm has a total of 126 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.61%, operating margin of 58.2%, and the pretax margin is 64.32%.
Protagonist Therapeutics Inc (PTGX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Protagonist Therapeutics Inc is 5.71%, while institutional ownership is 100.03%. The most recent insider transaction that took place on Mar 17 ’25, was worth 217,000. In this transaction Director of this company sold 4,000 shares at a rate of $54.25, taking the stock ownership to the 13,130 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Director proposed sale 4,000 for $54.78, making the entire transaction worth $219,120.
Protagonist Therapeutics Inc (PTGX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -130.94% per share during the next fiscal year.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators
Check out the current performance indicators for Protagonist Therapeutics Inc (PTGX). In the past quarter, the stock posted a quick ratio of 12.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.02. Likewise, its price to free cash flow for the trailing twelve months is 14.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 4.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Protagonist Therapeutics Inc (PTGX)
Analysing the last 5-days average volume posted by the [Protagonist Therapeutics Inc, PTGX], we can find that recorded value of 1.67 million was better than the volume posted last year of 1.05 million. As of the previous 9 days, the stock’s Stochastic %D was 24.50%. Additionally, its Average True Range was 2.80.
During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 34.12%, which indicates a significant increase from 21.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.92% in the past 14 days, which was lower than the 75.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.85, while its 200-day Moving Average is $41.93. Now, the first resistance to watch is $43.13. This is followed by the second major resistance level at $43.65. The third major resistance level sits at $44.66. If the price goes on to break the first support level at $41.60, it is likely to go to the next support level at $40.59. Should the price break the second support level, the third support level stands at $40.07.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats
There are currently 61,384K shares outstanding in the company with a market cap of 2.62 billion. Presently, the company’s annual sales total 434,430 K according to its annual income of 275,190 K. Last quarter, the company’s sales amounted to 170,640 K and its income totaled 131,670 K.
